Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...

US pharmaceutical company Eli Lilly and Co recently announced a roughly $200 million expansion of its manufacturing site in ...